Skip to main content
INGN
NASDAQ Industrial Applications And Services

Inogen Appoints New CFO and Key Commercial Leaders, Reaffirms 2026 Financial Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.11
Mkt Cap
$166.39M
52W Low
$5.34
52W High
$9.13
52W Position info
14% above low
Off High info
33% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

INGN is trading near its 52-week low of $5.34 (14% above the low).

Summary

Inogen announced the appointment of Jason Richardson as its new Chief Financial Officer, alongside new Chief Marketing Officer and VP of U.S. B2B Sales, signaling a strategic strengthening of its leadership team. The company also reaffirmed its financial outlook for Q1 and full-year 2026.


Key Events · Executive and Board Changes · INGN

  • New Chief Financial Officer Appointed

    Jason Richardson, formerly of Baxter International, has been named Executive Vice President, Chief Financial Officer, and Treasurer, effective April 6, 2026. His background includes senior finance roles in the medical device and healthcare industries.

  • Significant Equity Compensation for CFO

    Mr. Richardson will receive 200,000 restricted stock units (100,000 time-based RSUs and 100,000 performance-based PSUs) as inducement awards, valued at approximately $1.22 million based on the current stock price.

  • Key Commercial Leadership Additions

    Dominic Hulton has been appointed Chief Marketing Officer and Corey Moritz named Vice President, U.S. Business to Business Sales, strengthening the company's commercial and marketing capabilities.

  • Outgoing CFO Transition

    Michael Bourque will step down as CFO but remain as a Senior Advisor through June 30, 2026, to ensure a smooth transition, with no disagreements cited.


Analysis · INGN · Industrial Applications And Services

This 8-K details a significant leadership restructuring at Inogen, bringing in experienced executives to key roles. The appointment of Jason Richardson as CFO, with his background in medical device finance at Baxter and Hillrom, is a strategic move to support the company's growth initiatives. The substantial equity compensation package for Mr. Richardson underscores the company's commitment to attracting top talent. Additionally, the new Chief Marketing Officer and VP of U.S. B2B Sales are expected to bolster commercial execution and global brand reach. The reaffirmation of the 2026 financial outlook, following a recent return to positive Adjusted EBITDA, provides a strong signal of management's confidence in its operational trajectory and financial stability. Investors should view these changes as a concerted effort to drive the company's next phase of growth.

At the time of this filing, INGN was trading at $6.11 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $166.4M. The 52-week trading range was $5.34 to $9.13. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INGN - Latest Insights

INGN
Jul 01, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.70
Real-time Price: $6.15 info
Change: -$0.550 (-8%) info
Market Cap: $166.508M info
INGN
Jun 11, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.13
Real-time Price: $6.15 info
Change: +$0.020 (+0.33%) info
Market Cap: $166.508M info
INGN
May 08, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.02
Real-time Price: $6.15 info
Change: -$0.870 (-12%) info
Market Cap: $166.508M info
INGN
May 07, 2026, 4:47 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.05
Real-time Price: $6.15 info
Change: -$0.900 (-13%) info
Market Cap: $166.508M info
INGN
May 07, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.05
Real-time Price: $6.15 info
Change: -$0.900 (-13%) info
Market Cap: $166.508M info